Hormonal
GLP-1 receptor agonists (e.g., Exenatide, Liraglutide, Lixisenatide) lower HbA1c, promote weight loss, and reduce hypoglycemia risk by stimulating insulin secretion and increasing satiety.
GLP-1 receptor agonists are injectable medications that help lower blood sugar, promote weight loss, and reduce the risk of hypoglycemia. They work by mimicking a hormone that increases insulin, decreases glucagon, and makes you feel full. They are effective for both weight loss and glycemic control, with similar safety profiles in elderly and younger patients.
GLP-1 receptor agonists, including exenatide and liraglutide, can reduce hemoglobin A1c (HbA1c) levels by 0.8% to 1.5% [112]. GLP-1 receptor agonists are effective in the regulation of glucose metabolism, such as stimulating insulin production, inhibiting glucagon release, slowing nutrient absorption, and increasing feelings of satiety [94].
Why this rating
Described as 'ideal' for management due to efficacy, tolerability, and low hypoglycemia risk.
Source
Risk Factors Contributing to Type 2 Diabetes and Recent Advances in the Treatment and Prevention
Yanling Wu et al. · International Journal of Medical Sciences · 2014
DOI 10.7150/ijms.10001
More from this paper
- Metformin is the first-line therapy for Type 2 Diabetes, improving glycemic control, increasing insulin sensitivity, and reducing cardiovascular risk and mortality.Strong
- Obesity is the most important modifiable risk factor for Type 2 Diabetes, influencing insulin resistance and disease progression.Strong
- SGLT2 inhibitors (e.g., Dapagliflozin) lower blood glucose by preventing renal glucose reabsorption, resulting in reduced HbA1c, fasting plasma glucose, blood pressure, and body weight.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →